三个月融两轮，帕母医疗完成新一轮千万美金加轮融资

Core Insights - Pamu Medical has successfully completed a new round of financing amounting to tens of millions of dollars, led by EQT, a European private equity firm, with continued support from Sequoia Capital [1][3] - The funds raised will primarily be used for Pamu Medical's overseas market expansion, including global clinical registration, product indication expansion, and deepening industrialization systems [1][4] Company Development - Pamu Medical's CEO, Lian Jia, emphasized the importance of results-oriented progress and the commitment to advancing product transformation and global layout, ensuring that valuable Chinese original technologies can operate in broader markets [3][7] - Since its establishment in 2013, Pamu Medical has focused on global innovation, creating a closed loop of "R&D - Clinical - Market" [3][4] - The company's core technology, Percutaneous Pulmonary Artery Denervation (PADN), has been included in authoritative guidelines and has received CE-MDR certification from the EU, as well as humanitarian device exemption (HUD) from the FDA and market approval from the National Medical Products Administration (NMPA) in 2023 [3][4] Product and Market Strategy - Pamu Medical is constructing a global development pathway that is "verifiable, sustainable, and integrable into international standards," with successful commercialization of PADN products in China and ongoing efforts to penetrate international markets [4][5] - The recent financing will support Pamu Medical's strategy of "technology internationalization + path standardization," solidifying its position as a platform for Chinese original medical technology in the global healthcare system [4][5] Investor Perspective - EQT's Executive Director, Zoe Zhu, expressed confidence in Pamu Medical's innovative capabilities in the medical device sector, highlighting the potential of the PADN product in addressing unmet needs in the fields of pulmonary hypertension and heart failure [5][6] - Pamu Medical's Chairman, Cynthia Chen, acknowledged the challenges of establishing Chinese original technology as international standards but expressed confidence in the company's commitment to clinical value and innovation for global patients [7]